J&J raises annual profit forecast on strong cancer drug demand

Explore stories from Atlantic Canada.

Bruce Cockburn: 50 years of music, spirituality and social justice | SaltWire - Johnson & Johnson on Tuesday raised its 2023 profit forecast, banking on growing demand for its newer cancer treatments such as Carvykti and Tecvayli and recorded a $21 billion gain from the spin off of its consumer health unit.

Investors are focused on how Johnson & Johnson, now a standalone pharmaceutical and medical devices company, will reach its goal of $57 billion in drug sales by 2025. The company is facing a potential slowdown in sales of its arthritis drug Stelara after the launch of biosimilars. Excluding its consumer health unit, the company now expects 2023 adjusted profit of $10.07 to $10.13 per share, compared with its previous outlook of $10.00 to $10.10 per share.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

SaltWire Network /  🏆 45. in CA

Philippines Latest News, Philippines Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Pope Francis calls for humanitarian corridors to help those under siege in GazaExplore stories from Atlantic Canada.
Read more »

Soccer-Clement appointed manager at RangersExplore stories from Atlantic Canada.
Read more »

Pope Francis calls for humanitarian corridors to help those under siege in GazaExplore stories from Atlantic Canada.
Read more »

TikTok details disinformation steps taken after EU demandExplore stories from Atlantic Canada.
Read more »

Putin says suggestions of U.S. war against Russia and China are nonsenseExplore stories from Atlantic Canada.
Read more »

Putin says suggestions of U.S. war against Russia and China are nonsenseExplore stories from Atlantic Canada.
Read more »